Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion
Portfolio Pulse from Vandana Singh
Roche Holdings AG's Phase 3 OCARINA II trial evaluating Ocrevus as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with multiple sclerosis. The subcutaneous injection was shown to be non-inferior to Ocrevus given by intravenous infusion. The investigational subcutaneous formulation combines Ocrevus with Halozyme Therapeutics Inc's Enhanze drug delivery technology.
July 13, 2023 | 1:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics' Enhanze drug delivery technology is used in Roche's Ocrevus subcutaneous injection, which could potentially boost Halozyme's stock.
Halozyme's Enhanze drug delivery technology is used in Roche's Ocrevus subcutaneous injection. The successful trial results could potentially increase the demand for Halozyme's technology, leading to increased revenues and a positive impact on its stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Roche's successful Phase 3 trial of Ocrevus subcutaneous injection could potentially expand its usage in MS centers, positively impacting the company's stock.
The successful trial results of Ocrevus subcutaneous injection could lead to increased usage of the drug, especially in MS centers with IV capacity limitations or without IV infrastructure. This could potentially increase Roche's revenues and positively impact its stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100